干扰素α1b与α2b治疗慢性丙型肝炎的最小成本分析

Cost-minimization Analysis of Interferon α1b and Interferon α2b in the Treatment of Chronic Hepatitis C

目的:比较干扰素α1b与α2b治疗慢性丙型肝炎的经济性。方法:采用回顾性研究方法,选择114例接受干扰素治疗的慢性丙型肝炎患者,将其中采用干扰素α1b治疗的60例作为A组,采用干扰素α2b治疗的54例作为B组,比较两组患者的丙型肝炎病毒(HCV)-RNA转阴率、丙氨酸转氨酶(ALT)复常率和不良反应发生率,并进行药物经济学分析。结果:A组患者治疗4、12、24、36、48周时的HCV-RNA转阴率分别为55.00%、71.67%、63.33%、61.67%、65.00%,B组患者在上述各时间的HCV-RNA转阴率分别为64.81%、66.67%、62.96%、55.56%、61.11%,组间比较差异均无统计学意义(P>0.05);治疗结束时,A组患者的ALT复常率为95.23%,B组为96.10%,组间比较差异无统计学意义(P>0.05);两组患者各种不良反应发生率比较,差异均无统计学意义(P>0.05),故采用最小成本法进行药物经济学分析。A组的治疗成本为13 216.56元,B组为7 929.60元,B组的成本明显低于A组;敏感度分析得到同样的结果。结论:干扰素α2b治疗慢性丙型肝炎较干扰素α1b更为经济。

OBJECTIVE：To compare the economics of interferon α1b and α2b in the treatment of chronic hepatitis C. METHODS：By retrospective study,114 patients with chronic hepatitis C who received interferon were selected,60 patients received interferon α 1b were divided into group A and 54 patients received interferon α 2b were divided into group B. Negative conversion rate of HCV-RNA,normalization rate of ALT and the incidence of ADR in 2 groups were compared,and pharmacoeconomic analysis was conducted. RESULTS：Negative conversion rates of HCV-RNA in group A in 4,12,24,36,48 weeks were 55.00%,71.67%,63.33%,61.67% and 65.00%,group B were 64.81%,66.67%,62.96%,55.56% and 61.11%,respectively,there were no significant differences between 2 groups（P〉0.05）;after treatment,normalization rate of ALT in group A was 95.23%,group B was96.10%,there was no significant difference between 2 groups（P〉0.05）;and there were no significant differences in the incidence of ADR between 2 groups（P〉0.05）,so cost-minimization analysis was used to evaluate pharmacoeconomics. Therapy cost in group A was 13 216.56 yuan,group B was 7 929.60 yuan,group B was lower to group A;sensitivity analysis received the same results. CONCLUSIONS：Interferon α2b is more economical than α1b in the treatment of chronic hepatitis C.